The Role of Long Non-coding RNA in Acute Myeloid Leukemia: Mechanisms, Diagnostic Potential, and Therapeutic Implications

Abstract

Context: Acute myeloid leukemia (AML) is a heterogeneous and aggressive form of leukemia characterized by the abnormal proliferation of immature myeloid cells. The identification of reliable biomarkers for early diagnosis and prognosis is essential for improving patient outcomes. Evidence Acquisition: Emerging evidence suggests that long non-coding RNAs (lncRNAs), particularly tumor suppressor candidate 7 (TUSC7), play a significant role in cancer biology, including AML. Studies consistently show that TUSC7 is significantly downregulated in AML patients, suggesting its role as a tumor suppressor. Results: The diagnostic potential of TUSC7 was highlighted in multiple studies, with receiver operating characteristic (ROC) curve analysis showing promising sensitivity and specificity in distinguishing AML patients from healthy individuals. While preliminary evidence suggests that lower TUSC7 expression may be linked to worse survival outcomes, further research is required to confirm its prognostic value. Long non-coding RNAs TUSC7 shows potential as a biomarker for AML, with its downregulation correlating with disease progression. Conclusions: Although promising as a diagnostic tool, further studies are necessary to validate its use in prognosis and to explore therapeutic interventions targeting TUSC7. As research on TUSC7 advances, it may offer new avenues for personalized treatment strategies in AML.